Astellas Pharma Inc. today announced that the Supreme Court has dismissed a final appeal by Taiyo Yakuhin Co., Ltd. against a patent infringement lawsuit for its oral cephalosporin antibiotic cefdinir. It implies that Astellas won this lawsuit.
Cefdinir is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.
Cefdinir is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.
No comments:
Post a Comment